BIOMAT Database Logo BIOMAT Database Logo

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations. 2013

Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA.

BMS-986001 is a novel HIV nucleoside reverse transcriptase inhibitor (NRTI). To date, little is known about its resistance profile. In order to examine the cross-resistance profile of BMS-986001 to NRTI mutations, a replicating virus system was used to examine specific amino acid mutations known to confer resistance to various NRTIs. In addition, reverse transcriptases from 19 clinical isolates with various NRTI mutations were examined in the Monogram PhenoSense HIV assay. In the site-directed mutagenesis studies, a virus containing a K65R substitution exhibited a 0.4-fold change in 50% effective concentration (EC50) versus the wild type, while the majority of viruses with the Q151M constellation (without M184V) exhibited changes in EC50 versus wild type of 0.23- to 0.48-fold. Susceptibility to BMS-986001 was also maintained in an L74V-containing virus (0.7-fold change), while an M184V-only-containing virus induced a 2- to 3-fold decrease in susceptibility. Increasing numbers of thymidine analog mutation pattern 1 (TAM-1) pathway mutations correlated with decreases in susceptibility to BMS-986001, while viruses with TAM-2 pathway mutations exhibited a 5- to 8-fold decrease in susceptibility, regardless of the number of TAMs. A 22-fold decrease in susceptibility to BMS-986001 was observed in a site-directed mutant containing the T69 insertion complex. Common non-NRTI (NNRTI) mutations had little impact on susceptibility to BMS-986001. The results from the site-directed mutants correlated well with the more complicated genotypes found in NRTI-resistant clinical isolates. Data from clinical studies are needed to determine the clinically relevant resistance cutoff values for BMS-986001.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D024921 Drug Resistance, Multiple, Viral The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation. Drug Resistance, Extensive, Viral,Drug Resistance, Extensively, Viral,Extensive Antiviral Drug Resistance,Extensively Antiviral Drug Resistance,Multidrug Resistance, Viral,Multiple Antiviral Drug Resistance,Resistance, Viral Multidrug,Viral Multidrug Resistance,Viral Multidrug Resistances

Related Publications

Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.
May 2014, International journal of toxicology,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
February 2010, The Journal of antimicrobial chemotherapy,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens.
September 2004, The Journal of antimicrobial chemotherapy,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanisms.
March 2007, Current opinion in HIV and AIDS,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
[HIV-1 polymorphism and development of resistance mutations against non-nucleoside reverse transcriptase inhibitor, efavirenz].
February 2005, The Japanese journal of antibiotics,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
January 2016, The lancet. HIV,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations.
October 2011, BMC bioinformatics,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
December 2015, Antimicrobial agents and chemotherapy,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs.
January 2005, Antiviral chemistry & chemotherapy,
Zhufang Li, and Brian Terry, and William Olds, and Tricia Protack, and Carol Deminie, and Beatrice Minassian, and Beata Nowicka-Sans, and Yongnian Sun, and Ira Dicker, and Carey Hwang, and Max Lataillade, and George J Hanna, and Mark Krystal
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
January 2015, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!